Clinical Trials Logo

Eczema clinical trials

View clinical trials related to Eczema.

Filter by:

NCT ID: NCT00232011 Completed - Atopic Dermatitis Clinical Trials

Extension Study to Assess Safety and Efficacy of Pimecrolimus in Adult Patients With Atopic Dermatitis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of pimecrolimus cream will be evaluated in Japanese adult patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

NCT ID: NCT00231998 Completed - Atopic Dermatitis Clinical Trials

Extension Study of Pimecrolimus Cream in Pediatric Patients With Atopic Dermatitis

Start date: May 2004
Phase: Phase 3
Study type: Interventional

Pimecrolimus, which is an ascomycin derivative, is an anti-inflammatory non-steroidal agent. In this study, the long-term safety and efficacy of Pimecrolimus cream will be evaluated in Japanese pediatric patients with atopic dermatitis. This study is a 6-month extension study following core study. THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES

NCT ID: NCT00226707 Completed - Clinical trials for Chronic Hand Dermatitis

Pimecrolimus Cream 1% in Patients (18 Years of Age and Over) With Mild to Moderate Chronic Hand Dermatitis

Start date: July 2004
Phase: Phase 3
Study type: Interventional

Topical steroids are standard of care for Chronic Hand Dermatitis, but long-term use is associated with adverse effects. This study will assess the efficacy and safety of pimecrolimus cream 1% in patients with mild-to-moderate chronic hand dermatitis.

NCT ID: NCT00226057 Completed - Dermatitis, Atopic Clinical Trials

Efalizumab for Moderate to Severe Atopic Dermatitis

Start date: June 2005
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine if Raptiva will have beneficial effects in the treatment of patients with moderate to severe atopic dermatitis.

NCT ID: NCT00224432 Completed - Atopic Dermatitis Clinical Trials

Double-Blind, Parallel, Randomised Study to Investigate the Effect of Oral Probiotics in Infants With Atopic Dermatitis

Start date: March 2001
Phase: N/A
Study type: Interventional

To study the effect of supplementation of a hydrolyzed formula with probiotic bacteria on clinical and immunological parameters in infants with AD with and without CMA and to compare effectiveness of different strains of probiotics.

NCT ID: NCT00200954 Completed - Asthma Clinical Trials

Primary Prevention of Atopic Disease by Perinatal Administration of Probiotics

Start date: January 2004
Phase: N/A
Study type: Interventional

Administration of probiotics to pregnant women from an atopic family and subsequently to their high-risk newborns results in prevention of the incidence or in a decrease of the severity of atopic disease during infancy.

NCT ID: NCT00200928 Completed - Asthma Clinical Trials

Asthma, a Disease Due to a Lack of Bacterial Infections in Childhood.

Start date: January 1999
Phase: N/A
Study type: Interventional

The degree of TH1-skewing by mycobacteria is controlles by NRAMP1 gene polymorphisms and related to the degree of inhibition of TH2-mediated disease.

NCT ID: NCT00189397 Completed - Clinical trials for Parthenium Dermatitis

Azathioprine Versus Corticosteroids in Parthenium Dermatitis

Start date: February 2003
Phase: N/A
Study type: Interventional

The dermatitis caused by the substances which come in contact with the skin is known as contact dermatitis. When such a reaction is caused by the agents suspended in the air, it is called air-borne contact dermatitis (ABCD). Parthenium hysterophorus at present is the commonest cause of ABCD in India though in some cases other plants have also been found to cause ABCD. Parthenium dermatitis is one of the major health problems in dermatology in our country. Though it has very little mortality, the disease normally continues to persist with variable remissions and relapses causing great distress and morbidity. Corticosteroids, topical and systemic have been the mainstay of the treatment so far. Therefore, the patients with ABCD who have to take corticosteroids for long periods of time tend to develop severe and sometimes irreversible side effects of the therapy. Azathioprine is an immunosuppressive drug which acts by inhibiting the T lymphocytes. In our previous studies we have been able to induce remissions in these patients with azathioprine used as daily as well as monthly bolus dose, without having to use systemic corticosteroids. The side effect with azathioprine in these studies were almost absent. We have therefore planned to study the therapeutic efficacy of azathioprine weekly pulse doses versus daily azathioprine in achieving remissions in patients having Parthenium dermatitis and to monitor the side effects of both the regimens.

NCT ID: NCT00180141 Completed - Atopic Dermatitis Clinical Trials

Elidel-Study: Elidel in Patients With Atopic Dermatitis

Start date: April 2005
Phase: Phase 4
Study type: Interventional

Atopic dermatitis is a common disease. Emollients and Elidel have both shown to be effective to treat this disease. The research question is, whether the effective component (Elidel) is better than the emollient to improve the skin function.

NCT ID: NCT00179959 Completed - Atopic Dermatitis Clinical Trials

The Impact of Treating Staphylococcus Aureus Infection and Colonization on the Clinical Severity of Atopic Dermatitis

Start date: September 2005
Phase: Phase 4
Study type: Interventional

Staphylococcus aureus (S. aureus) infection is perceived not only as a common secondary complication of atopic dermatitis (AD), but also as a culprit in the worsening of this condition. In addition, the recent development of community acquired methicillin-resistant S. aureus (CA-MRSA) has presented a new challenge to our management of AD, both in treatment of acute infections and maintenance therapy. The investigators would like to perform a randomized investigator-blinded placebo-controlled study of children aged 6 months to 17 years with moderate to severe atopic dermatitis with clinical signs of secondary bacterial infection to study: 1) the prevalence of CA-MRSA in our patient population; 2) the relationship of sensitivity of the S. aureus organism cultured from the infected lesion(s) to clinical response to oral cephalexin therapy and severity of the AD; and 3) whether concurrent treatment of S. aureus infection initially with nasal mupirocin ointment and sodium hypochlorite (bleach) baths can result in long-term S. aureus eradication and clinical stability.